The beneficial effects of Xolair® (Omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV - The Israeli arm of the INNOVATE study
Zev M. Sthoeger, Abraham Eliraz, Ilan Asher, Neville Berkman, Daniel Elbirt*
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
13Scopus
citations
Fingerprint
Dive into the research topics of 'The beneficial effects of Xolair® (Omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV - The Israeli arm of the INNOVATE study'. Together they form a unique fingerprint.